GET DAILY SIGNALSHeron Therapeutics (HRTX) Narrows Q3 Loss to $5 Million Despite Softer Sales
Key Takeaways
- Heron Therapeutics reported a net loss of $5.0 million for the third quarter of 2026, a sharp improvement from the $17.5 million net loss recorded a year earlier.
- Net product sales came in at $35.3 million, down from $38.2 million in the prior-year quarter and below analyst consensus expectations.
- Net loss per share was $0.03, narrowing meaningfully from a loss of $0.10 per share in the same period of 2025.
- Gross profit of $26.3 million was essentially flat year over year, supported by lower cost of product sales.
- Shares rose sharply in premarket trading following the release, reflecting an investor focus on the narrowed loss rather than the softer revenue line.
Why This Quarter Matters
Heron Therapeutics is a commercial-stage biotechnology company focused on acute care and oncology therapies, anchored by products such as ZYNRELEF, APONVIE, and CINVANTI. Its third-quarter 2026 report carries added weight because the company has spent much of the year navigating competitive pressure in its oncology franchise while working to grow its acute care portfolio. Earlier in 2026, management withdrew its full-year guidance following a court decision that raised uncertainty around potential generic competition, making each quarterly print a key checkpoint for the durability of revenue and the trajectory of cash resources. Investors are watching whether cost discipline and narrowing losses can offset a declining top line. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The Numbers in Detail
For the third quarter ended September 30, 2026, Heron Therapeutics reported net product sales of $35.25 million, down from $38.21 million in the prior-year period. This figure came in below analyst consensus estimates. The company posted a net loss of $5.0 million, a substantial narrowing from the $17.5 million net loss recorded in the third quarter of 2025. Net loss per share, basic and diluted, was $0.03, compared with a loss of $0.10 per share in the year-ago quarter, and was roughly in line with the consensus estimate of a $0.03 loss.
Gross profit held steady at $26.3 million, supported by a decline in cost of product sales to $9.0 million from $11.9 million a year earlier. Total operating expenses decreased to $28.0 million from $30.4 million, driven by reductions across research and development, general and administrative, and sales and marketing spending. For the nine months ended September 30, 2026, net product sales totaled $107.6 million versus $114.3 million in the prior-year period, while the net loss was $18.6 million compared with $17.2 million a year ago. From what I see, the expense controls are the standout feature here.
How the Market Reacted
Shares of HRTX rose sharply in premarket trading following the release, a reaction that suggested investors weighed the significantly narrower net loss more heavily than the year-over-year decline in product sales. The improved bottom line, aided by disciplined cost control and lower operating expenses, offered a contrast to a revenue line that continues to face headwinds in the oncology segment. The stock has nonetheless been under sustained pressure over the past year, reflecting concerns about generic competition, the withdrawn full-year guidance, and a shrinking cash position. Sentiment around the quarter appeared focused on the company's ability to preserve cash and stabilize the business while strategic alternatives remain under review. I’m watching this closely as the acute care side shows more resilience.
What to Watch Going Forward
Looking ahead, investors should monitor whether Heron Therapeutics can sustain its narrowed losses even as net product sales trend lower. The acute care franchise, led by ZYNRELEF and APONVIE, has been the primary growth engine, while CINVANTI faces branded competition and the oncology segment has been declining. Sustaining acute care momentum will be central to offsetting those pressures.
Cash management and covenant compliance remain critical watch items. With full-year guidance withdrawn and strategic alternatives under consideration, the company's quarterly disclosures around cash, spending, and adjusted EBITDA will carry outsized importance. Investors should also track any updates on the timing and potential impact of generic competition, which management has flagged as a key source of uncertainty.
Finally, watch for signals on expense discipline and gross margin trends. Lower cost of product sales supported gross profit this quarter, but sustaining that improvement will depend on product mix and inventory management. These factors, rather than headline revenue alone, are likely to shape how the market interprets Heron's progress in the quarters ahead. One thing that stands out is how the company is managing through the uncertainty.
Using AI Tools in My Analysis
In my research process, I frequently rely on Tickeron’s AI Screener to quickly filter for comparable names and spot patterns in volatility or fundamentals that might otherwise take hours to uncover manually. It helps me put individual results like these into broader context without replacing my own judgment.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
Momentum Indicator for HRTX turns negative, indicating new downward trend
HRTX saw its Momentum Indicator move below the 0 level on October 21, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 80 similar instances where the indicator turned negative. In 73 of the 80 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Moving Average Convergence Divergence Histogram (MACD) for HRTX turned negative on October 21, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 39 similar instances when the indicator turned negative. In 32 of the 39 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.
HRTX moved below its 50-day moving average on October 22, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for HRTX crossed bearishly below the 50-day moving average on October 29, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where HRTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 60 cases where HRTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
Following a +2.73% 3-day Advance, the price is estimated to grow further. Considering data from situations where HRTX advanced for three days, in 181 of 215 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
HRTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 109 of 141 cases where HRTX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 77%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 78 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (9.496) is normal, around the industry mean (3.498). P/E Ratio (-1.542) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.387) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 89 (best 1 - 100 worst), indicating slightly worse than average price growth. HRTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. HRTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of polymer technologies
Industry Biotechnology
Advertisement